XML 213 R5.htm IDEA: XBRL DOCUMENT v3.25.0.1
CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
shares in Thousands
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Income Statement [Abstract]    
Revenue $ 1,000,000 $ 0
Operating Expenses:    
Research and development 11,334,000 12,734,000
General and administrative 12,075,000 12,974,000
Operating expenses 23,409,000 25,708,000
Operating loss (22,409,000) (25,708,000)
Other income (expense):    
Investment income, net 1,883,000 2,724,000
Other expense, net (257,000) (186,000)
Total other income 1,626,000 2,538,000
Net loss before benefit from income taxes and noncontrolling interests (20,783,000) (23,170,000)
Benefit from income taxes (798,000) (2,330,000)
Net loss (19,985,000) (20,840,000)
Less - net income (loss) attributable to noncontrolling interests 0 0
Net loss attributable to Lisata Therapeutics, Inc. common stockholders $ (19,985,000) $ (20,840,000)
Basic and diluted loss per share:    
Lisata Therapeutics, Inc. common stockholders - basic (in dollars per share) $ (2.40) $ (2.58)
Lisata Therapeutics, Inc. common stockholders - diluted (in dollars per share) $ (2.40) $ (2.58)
Weighted average common shares outstanding:    
Basic (in shares) 8,329 8,073
Diluted (in shares) 8,329 8,073